Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT: NCT05794880 · RECRUITING

NCT IDNCT05794880
StatusRECRUITING
Start Date2023-05-01
Completion2032-05

Brief Summary

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Frequently Asked Questions

What is MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing?

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing is a clinical trial registered under NCT05794880. Current status: RECRUITING.

What is the status of NCT05794880?

The current status of NCT05794880 (MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing) is: RECRUITING.

When did MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing start?

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing started on 2023-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑